Compare UiPath Inc (PATH) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Tilray Brands Inc — how do they compare? UiPath Inc trades at $13.45 (market cap $6.91B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: UiPath Inc is far larger — about 13× Tilray Brands Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Tilray Brands Inc for 31 Days on average.
| PATH | TLRY | |
|---|---|---|
Market Cap | $6.91B | $530.54M |
Volume | 34,321,250 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $19.29 | $21.00 |
52-Week Low | $9.38 | $3.57 |
Typical Hold Time | 139 Days | 31 Days |
Enterprise Value | $5.70B | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.48, up 3.14% today, showing technical bullish momentum despite mixed earnings results. The company demonstrates strong revenue growth from $892M in 2022 to $1.43B in 2025, with improving profit margins turning positive in 2026. Recent partnerships with Snowflake and BDO highlight expansion in AI orchestration capabilities, while analyst sentiment remains cautious with 67% hold ratings.
PATH offers growth potential through enterprise automation leadership and AI integration, but faces execution risks and competitive pressure. The stock trades below consensus price target of $15.13, representing 12% upside, though negative cash flow trends and valuation concerns warrant careful monitoring of quarterly execution against guidance.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
